Global Epoetin (Eritropoyetin) Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Epoetin (Eritropoyetin) Market Insights, Forecast to 2034
Epoetin can be given intravenously or, more conveniently, subcutaneously, when a 25–50% lower dose can be used.
Global Epoetin (Eritropoyetin) market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Epoetin (Eritropoyetin) industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Epoetin (Eritropoyetin) key manufacturers include Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon and Intas Pharmaceuticals, etc. Amgen, Epoetin, Abcam are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Epoetin (Eritropoyetin) were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Epoetin (Eritropoyetin) market and estimated to attract more attentions from industry insiders and investors.
Epoetin (Eritropoyetin) can be divided into Epoetin-alfa, Epoetin-beta and Darbepoetin Alfa,, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Epoetin (Eritropoyetin) is widely used in various fields, such as Anemia (Cancer and HIV Treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound Healing),, etc. Anemia (Cancer and HIV Treatment) provides greatest supports to the Epoetin (Eritropoyetin) industry development. In 2022, global % sales of Epoetin (Eritropoyetin) went into Anemia (Cancer and HIV Treatment) filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Epoetin (Eritropoyetin) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Epoetin (Eritropoyetin) market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

Amgen
Epoetin
Abcam
Johnson & Johnson
Hospira Inc
Roche
LG Life Sciences Ltd
Biocon
Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Ranbaxy Laboratories Ltd
Celltrion, Inc
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin Alfa
Anemia (Cancer and HIV Treatment)
Kidney Disorders (ESRD and Dialysis)
Others (Neural Disease and Wound Healing)
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Epoetin (Eritropoyetin) plant distribution, commercial date of Epoetin (Eritropoyetin), product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Epoetin (Eritropoyetin) introduction, etc. Epoetin (Eritropoyetin) Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Epoetin (Eritropoyetin)
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Epoetin (Eritropoyetin) market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Epoetin (Eritropoyetin) industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Epoetin (Eritropoyetin) key manufacturers include Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon and Intas Pharmaceuticals, etc. Amgen, Epoetin, Abcam are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Epoetin (Eritropoyetin) were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Epoetin (Eritropoyetin) market and estimated to attract more attentions from industry insiders and investors.
Epoetin (Eritropoyetin) can be divided into Epoetin-alfa, Epoetin-beta and Darbepoetin Alfa,, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Epoetin (Eritropoyetin) is widely used in various fields, such as Anemia (Cancer and HIV Treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound Healing),, etc. Anemia (Cancer and HIV Treatment) provides greatest supports to the Epoetin (Eritropoyetin) industry development. In 2022, global % sales of Epoetin (Eritropoyetin) went into Anemia (Cancer and HIV Treatment) filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Epoetin (Eritropoyetin) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Epoetin (Eritropoyetin) market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Amgen
Epoetin
Abcam
Johnson & Johnson
Hospira Inc
Roche
LG Life Sciences Ltd
Biocon
Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Ranbaxy Laboratories Ltd
Celltrion, Inc
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin Alfa
Segment by Application
Anemia (Cancer and HIV Treatment)
Kidney Disorders (ESRD and Dialysis)
Others (Neural Disease and Wound Healing)
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Epoetin (Eritropoyetin) plant distribution, commercial date of Epoetin (Eritropoyetin), product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Epoetin (Eritropoyetin) introduction, etc. Epoetin (Eritropoyetin) Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Epoetin (Eritropoyetin)
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
